Biosimilars: US FDA Asked To Clarify Thinking On Pediatric Studies, Indication Carve-Outs
Executive Summary
Draft guidance raises questions about Pediatric Research Equity Act obligations of biosimilar applicants and reference product holders, comments say; industry seeks clarity on review of indications with unexpired exclusivity and requests allowances for situations where a biosimilar's dosage form or labeled conditions of use do not align exactly with those of the reference product.
You may also be interested in...
Tentative Biosimilar Approvals Under Consideration By FDA
Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.
Tentative Biosimilar Approvals A Consideration for the US FDA
Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.
Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity
The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.